Recursion Pharmaceuticals raised $50 million from Nvidia via a PIPE that placed the AI biotech squarely into the investor fervor surrounding the tech company.
Recursion said Wednesday morning it now plans to work with Nvidia on the software company’s cloud service that uses generative AI for drug discovery. Recursion brings a massive biochemical dataset through which Nvidia’s drug discovery foundation models can be trained.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters